1. Home
  2. QTTB vs CRIS Comparison

QTTB vs CRIS Comparison

Compare QTTB & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QTTB
  • CRIS
  • Stock Information
  • Founded
  • QTTB 2015
  • CRIS 2000
  • Country
  • QTTB United States
  • CRIS United States
  • Employees
  • QTTB N/A
  • CRIS N/A
  • Industry
  • QTTB Biotechnology: Pharmaceutical Preparations
  • CRIS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • QTTB Health Care
  • CRIS Health Care
  • Exchange
  • QTTB Nasdaq
  • CRIS Nasdaq
  • Market Cap
  • QTTB 18.9M
  • CRIS 21.3M
  • IPO Year
  • QTTB N/A
  • CRIS 2000
  • Fundamental
  • Price
  • QTTB $1.44
  • CRIS $1.81
  • Analyst Decision
  • QTTB Hold
  • CRIS Strong Buy
  • Analyst Count
  • QTTB 8
  • CRIS 2
  • Target Price
  • QTTB $24.00
  • CRIS $16.50
  • AVG Volume (30 Days)
  • QTTB 123.8K
  • CRIS 137.6K
  • Earning Date
  • QTTB 08-07-2025
  • CRIS 07-31-2025
  • Dividend Yield
  • QTTB N/A
  • CRIS N/A
  • EPS Growth
  • QTTB N/A
  • CRIS N/A
  • EPS
  • QTTB N/A
  • CRIS N/A
  • Revenue
  • QTTB N/A
  • CRIS $11,202,000.00
  • Revenue This Year
  • QTTB N/A
  • CRIS N/A
  • Revenue Next Year
  • QTTB N/A
  • CRIS $10.67
  • P/E Ratio
  • QTTB N/A
  • CRIS N/A
  • Revenue Growth
  • QTTB N/A
  • CRIS 14.17
  • 52 Week Low
  • QTTB $1.38
  • CRIS $1.02
  • 52 Week High
  • QTTB $53.79
  • CRIS $8.29
  • Technical
  • Relative Strength Index (RSI)
  • QTTB 36.08
  • CRIS 36.90
  • Support Level
  • QTTB $1.41
  • CRIS $1.50
  • Resistance Level
  • QTTB $1.63
  • CRIS $2.48
  • Average True Range (ATR)
  • QTTB 0.11
  • CRIS 0.21
  • MACD
  • QTTB -0.02
  • CRIS -0.07
  • Stochastic Oscillator
  • QTTB 8.89
  • CRIS 25.20

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

About CRIS Curis Inc.

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Share on Social Networks: